Demographic characteristics, disease activity, COVID-19 vaccines and biological treatment of patients included in the study, categorised by diagnosis and in total
| Rheumatoid arthritis (n=1178) | Psoriatic arthritis (n=587) | P value | Total (N=1765) | |
| Female, n (%) | 926 (78.6) | 318 (54.2) | <0.001 | 1244 (70.5) |
| Race, n (%) | 0.002 | |||
| Caucasian | 1104 (93.7) | 572 (97.3) | 1675 (94.9) | |
| Latin American | 51 (4.3) | 7 (1.2) | 58 (3.3) | |
| Others | 23 (2.0) | 9 (1.5) | 32 (1.8) | |
| Age (years) | 60.5±12.2 | 55.3±11.6 | <0.001 | 58.7±12.2 |
| Age, n (%) | <0.001 | |||
| < 45 | 137 (11.6) | 116 (19.8) | 253 (14.3) | |
| (45–65) | 633 (53.7) | 345 (58.8) | 978 (55.4) | |
| (65–75) | 268 (22.8) | 105 (17.8) | 373 (21.2) | |
| ≥75 | 140 (11.9) | 21 (3.6) | 161 (9.1) | |
| Rheumatic disease duration (years), median (IQR) | 11.9 (6.4–18.9) | 9.7 (5.1–15.9) | <0.001 | 11.1 (5.9–18.0) |
| Time from the first biological (years). median (IQR) | 4.6 (1.5–11.2) | 4.5 (2.0–8.4) | 0.532 | 4.5 (1.7–10.5) |
| Vaccine type | 0.317 | |||
| Pfizer | 665 (56.4) | 357 (60.8) | 1022 (58.0) | |
| AstraZeneca | 281 (23.9) | 122 (20.8) | 403 (22.8) | |
| Moderna | 176 (14.9) | 79 (13.5) | 255 (14.4) | |
| Janssen | 56 (4.8) | 29 (4.9) | 85 (4.8) | |
| Disease activity | ||||
| DAS28* | 3.33±1.47 | 3.00±1.45 | <0.001 | 3.22±1.47 |
| DAS28 categorised, n (%) | <0.001 | |||
| Remission (< 2.6) | 410 (34.8) | 263 (44.8) | 673 (38.1) | |
| Low activity (2.6–3.2) | 188 (16.0) | 89 (15.2) | 277 (15.7) | |
| Moderate activity (3.2–5.1) | 416 (35.3) | 178 (30.3) | 594 (33.7) | |
| High activity ≥5.1 | 164 (13.9) | 57 (9.7) | 221 (12.5) | |
| Biologics at vaccination | 888 (50.3) | |||
| TNF-i | 523 (44.4) | 365 (62.2) | 888 (50.3) | |
| IL-17-i | – | 118 (20.1) | 120 (6.8) | |
| Anti-CD20 | 99 (8.4) | – | 100 (5.7) | |
| IL-6-i | 190 (16.1) | – | 193 (10.9) | |
| T cell activation-i | 147 (12.5) | – | 148 (8.4) | |
| IL-12/23-i | – | 57 (9.7) | 57 (3.2) | |
| PDE4-i | – | 27 (4.6) | 27 (1.5) | |
| JAK-i | 214 (18.2) | 15 (2.6) | 229 (13.0) | |
| Number of biologics prior to vaccination | 0.109 | |||
| 1 | 844 (71.6) | 424 (72.2) | 1268 (71.8) | |
| 2 | 200 (17.0) | 99 (16.9) | 299 (16.9) | |
| 3 | 74 (6.3) | 47 (8.0) | 121 (6.9) | |
| 4 or more | 60 (5.1) | 17 (2.9) | 77 (4.4) |
*Prevaccination values.
IL-6-i, interleukin-6 inhibitor; IL-17-i, interleukin-17 inhibitor; IL-12/23-i, interleukin-12/23 inhibitor; JAK-i, Janus kinase inhibitor; PDE4-i, phosphodiesterase-4 inhibitor; T-cell activation-i, T-cell activation inhibitor; TNF-i, tumour necrosis factor inhibitor.